請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62037
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉振軒(Chen-Hsuan Liu) | |
dc.contributor.author | Yao-Chun Chien | en |
dc.contributor.author | 簡耀君 | zh_TW |
dc.date.accessioned | 2021-06-16T13:24:26Z | - |
dc.date.available | 2018-07-30 | |
dc.date.copyright | 2013-07-30 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-07-24 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62037 | - |
dc.description.abstract | 淋巴瘤是犬最常見的惡性腫瘤之一,形態學上與人類非何杰金氏淋巴瘤 (non-Hodgkin’s lymphoma)具有高度類似性。依照世界衛生組織分類法,瀰漫性大型B細胞淋巴瘤(diffuse large B cell lymphoma; DLBCL)為犬最常見的淋巴瘤。此外,濾泡型淋巴瘤(follicular lymphoma)、被套細胞淋巴瘤(mantle cell lymphoma)、邊緣區型淋巴瘤(marginal zone lymphoma)、與T區域型淋巴瘤(T-zone lymphoma)之臨床表徵屬於緩慢型淋巴瘤(indolent lymphoma)。
DLBCL在人類可區分為類生發中心B細胞型(germinal center B-cell-like)與類活化B細胞型(activated B-cell-like)兩種分子學亞型(molecular subtypes),前者之生物標記包含了CD10和Bcl-6,而MUM1與Bcl-2則為後者之標記。病人罹患GCB型DLBCL具有顯著較佳總存活率。 本研究為探討在犬淋巴瘤中,這四個蛋白質之免疫組織化學染色表現程度與預後之相關性。在收集的102例病例中,B細胞淋巴瘤占59例、T細胞型占41例、以及無顯著分型之淋巴瘤占2例,其中DLBCL為最常見的淋巴瘤類型。針對具有完整臨床資訊之53病例,進行CD10、Bcl-6、MUM1和Bcl-2之免疫組織化學染色。結果顯示,Bcl-2表現弱之淋巴瘤具有顯著較短的總存活時間(overall survival time),而CD10、Bcl-6、MUM1之表現皆與預後無關。此外,本研究亦證實世界衛生組織分類法之診斷與預後有顯著相關,其中緩慢型淋巴瘤不但總存活時間較非緩慢型(non-indolent)淋巴瘤長,且皆具有中等至強的Bcl-2表現程度。本研究的結果顯示,犬DLBCL並無法以CD10、Bcl-6、MUM1和Bcl-2區分為不同的分子學亞型,然而在所有種類的淋巴瘤中,Bcl-2具有預估臨床預後之潛力,其機制仍需進一步的研究加以探討。 | zh_TW |
dc.description.abstract | Lymphoma is one of the most common malignancies in dogs. Canine lymphoma bears a morphological resemblance to non-Hodgkin’s lymphoma in the human. Diffuse large B-cell lymphoma (DLBCL), according to the World Health Organization (WHO) classification, is the most common form of canine lymphoma. Furthermore, indolent lymphomas that are characterized by a slowly progressive clinical course include follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and T-zone lymphoma.
Human DLBCLs can be sorted into two molecular subtypes: germinal center B-cell-like (GCB) DLBCL and activated B-cell-like (ABC) DLBCL. CD10 and Bcl-6 are biomarkers for GCB-DLBCL, while ABC-DLBCL is representative of MUM1 or Bcl-2 expression. Patients diagnosed with GCB-DLBCL show a significant better overall survival rate than those diagnosed with ABC-DLBCL. The present study is to investigate the correlation between prognosis and expression of CD10, Bcl-6, MUM1 and Bcl-2 in canine lymphomas. A total of 102 cases met the inclusion criteria, with 59 of B-cell derivation, 41 of T-cell derivation, and 2 of null-cell derivation. DLBCL was the most common diagnosis based on the WHO criteria. Immunohistochemical stain for CD10, Bcl-6, MUM1 and Bcl-2 was performed on a total of 53 cases with a complete medical and follow-up record. The results indicated that none of the markers had a correlation with prognosis with the exception of Bcl-2. Bcl-2 expression had a significantly positive correlation with overall survival time. Moreover, indolent lymphomas not only showed prolonged overall survival over non-indolent lymphomas, but also were characterized by moderate or strong levels of Bcl-2 expression. In conclusion, we did not find molecular subtypes of canine DLBCL via CD10, Bcl-6, MUM1 and Bcl-2 expression. Among these four markers, only Bcl-2 had a potential prognostic value of canine lymphomas. The mechanism of Bcl-2 remains to be determined, though. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:24:26Z (GMT). No. of bitstreams: 1 ntu-102-R00644003-1.pdf: 9114899 bytes, checksum: 40c210e9c12b20ca13080c453207fbb2 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 中文摘要 I
Abstract II Abbreviation List VI Chapter 1. Introduction 1 Chapter 2. Background and Literature Review 4 2.1 Lymphomas 4 2.1.1 Lymphocyte development and maturation 4 2.1.2 Incidence and predilection 6 2.1.3 Risk factors 7 2.1.4 Clinical presentations 9 2.1.5 Prognostic factors 11 2.1.6 Treatments 14 2.1.7 Histological classification 16 2.2 Molecular biology 21 2.2.1 Cluster of differentiation 10 (CD10) and B-cell lymphoma 6 protein (Bcl-6) 21 2.2.2 Multiple myeloma oncogene-1 (MUM1) and B-cell lymphoma 2 protein (Bcl-2) 24 Chapter 3. Materials and Methods 29 3.1 Case collection 29 3.2 Histological evaluation 30 3.3 Immunohistochemistry (IHC) 30 3.4 Evaluation of immunohistochemical examination 32 3.5 Evaluation of response to chemotherapy, duration of first remission and overall survival time 33 3.6 Statistical analysis 34 Chapter 4. Results 36 4.1 Patients 36 4.2 Histological evaluation with immunophenotyping 38 4.3 CD10, Bcl-6, MUM1 and Bcl-2 expression 40 4.4 Survival data 42 Chapter 5. Discussion 47 Figures 56 Figure 1. Histopathological features of diffuse large B-cell lymphoma (DLBCL). 56 Figure 2. CD10 expression in canine normal tissues and lymphomas. 57 Figure 3. Bcl-6 expression in canine normal tissues and lymphomas. 58 Figure 4. MUM1 expression in canine normal tissues and lymphomas. 59 Figure 5. Bcl-2 expression in canine normal tissues and lymphomas. 60 Figure 6. Overall survival (OS) of 53 dogs with lymphoma according to the World Health Organization (WHO) pathological diagnosis. 62 Figure 7. OS according to the chemotherapy. 63 Figure 8. OS according to status for Bcl2 protein. 64 Tables 66 Table 1. The World Health Organization clinical staging system for canine lymphoma 66 Table 2. The Kiel classification (1978) 67 Table 3. The Working Formulation classification (1982) 68 Table 4. The updated Kiel classification (1991) 69 Table 5. The World Health Organization classification of canine lymphoma (2002) 70 Table 6. Signalments of the 102 dogs with lymphoma 71 Table 7. Anatomic locations of 142 specimens from 102 dogs with lymphoma 72 Table 8. Clinicopathological findings and disease staging at presentation of 53 dogs with a complete medical record 73 Table 9. Relation of tumor location to immunophenotype of canine lymphomas 74 Table 10. Correlation between the protein expressions, clinical and histological variables in lymphomas 75 Table 11. Correlation between the protein expressions in DLBCLs 76 Table 12. Univariate analysis of the influence of patient variables on OS 77 Table 13. Univariate analysis of the influence of histopathological variables on OS 78 Table 14. Correlation of protein expressions with OS and DFR by univariate analysis 79 Table 15. Univariate analysis of the effect of variables on DFR 80 Table 16. Pairwise comparisons of differences in OS between the WHO pathological diagnoses 82 Table 17. Clinical and histopathological variables based on the Bcl-2 expression 83 References 85 | |
dc.language.iso | en | |
dc.title | 犬淋巴瘤預後與CD10、Bcl-6、MUM1和Bcl-2表現之相關性 | zh_TW |
dc.title | The Correlation between Prognosis and Expression of CD10, Bcl-6, MUM1 and Bcl-2 in Canine Lymphomas | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 廖泰慶(Tai-Ching Liao),張清棟(Ching-Dung Chang),朱旆億(Pei-Yi Chu) | |
dc.subject.keyword | 犬淋巴瘤,免疫化學染色,CD10,Bcl-6,MUM1,Bcl-2,預後, | zh_TW |
dc.subject.keyword | Canine lymphoma,immunohistochemistry,CD10,Bcl-6,MUM1,Bcl-2,prognosis, | en |
dc.relation.page | 102 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-07-24 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 分子暨比較病理生物學研究所 | zh_TW |
顯示於系所單位: | 分子暨比較病理生物學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 8.9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。